Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma

Clinical and Experimental Immunology

Volumn 168, Issue 2, 2012, Pages 186-191

  Enomoto, K ^a   Sho, M ^a   Wakatsuki, K ^a   Takayama, T ^a   Matsumoto, S ^a   Nakamura, S ^a   Akahori, T ^a   Tanaka, T ^a   Migita, K ^a   Ito, M ^a   Nakajima, Y ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

CD45RO; Memory cells; Oesophagus; Prognosis; Surgery

Indexed keywords

CD45RO ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CELL COUNT; CELL INFILTRATION; DISEASE FREE SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; OVERALL SURVIVAL; PATIENT CODING; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; ANTIGENS, CD45; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 84859240566     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04565.x     Document Type: Article

References (35)

1. Okines A, Sharma B, Cunningham D. Perioperative management of esophageal cancer. Nat Rev Clin Oncol 2010; 7:231-8.
2. Pennathur A, Luketich JD. Resection for esophageal cancer: strategies for optimal management. Ann Thorac Surg 2008; 85:S751-6.
3. Klein CA, Stoecklein NH. Lessons from an aggressive cancer: evolutionary dynamics in esophageal carcinoma. Cancer Res 2009; 69:5285-8.
4. Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007; 25:4110-7.
5. Gros SJ, Kurschat N, Dohrmann T etal. Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma. Mol Cancer Ther 2010; 9:2037-45.
6. Tabernero J, Macarulla T, Ramos FJ, Baselga J. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 2005; 16:1740-8.
7. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007; 298:70-82.
8. Lurje G, Leers JM, Pohl A etal. Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. Ann Surg 2010; 251:857-64.
9. Ohigashi Y, Sho M, Yamada Y etal. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005; 11:2947-53.
10. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9:4404-8.
11. Tsuchikawa T, Ikeda H, Cho Y etal. Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival. Clin Exp Immunol 2011; 164:50-6.
12. Michie CA, McLean A, Alcock C, Beverley PC. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 1992; 360:264-5.
13. Pages F, Berger A, Camus M etal. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353:2654-66.
14. Galon J, Costes A, Sanchez-Cabo F etal. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4.
15. Lee HE, Chae SW, Lee YJ etal. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 2008; 99:1704-11.
16. Rauser S, Langer R, Tschernitz S etal. High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma. BMC Cancer 2010; 10:608.
17. Cho Y, Miyamoto M, Kato K etal. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 2003; 63:1555-9.
18. Zingg U, Montani M, Frey DM, Dirnhofer S, Went P, Oertli D. Influence of neoadjuvant radio-chemotherapy on tumor-infiltrating lymphocytes in squamous esophageal cancer. Eur J Surg Oncol 2009; 35:1268-72.
19. Yoshioka T, Miyamoto M, Cho Y etal. Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br J Cancer 2008; 98:1258-63.
20. Sobin LH, Gospodarowicz MK, Wittekind CH. TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, 2009.
21. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12:337-65.
22. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001; 22:269-76.
23. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10:281-7.
24. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007; 67:1883-6.
25. Yi KH, Chen L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 2009; 229:145-51.
26. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 2011; 241:180-205.
27. Yamato I, Sho M, Nomi T etal. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009; 101:1709-16.
28. Bennett MW, O'Connell J, O'Sullivan GC etal. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160:5669-75.
29. Chan KW, Lee PY, Lam AK, Law S, Wong J, Srivastava G. Clinical relevance of Fas expression in oesophageal squamous cell carcinoma. J Clin Pathol 2006; 59:101-4.
30. Gholamin M, Moaven O, Memar B etal. Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg 2009; 33:1439-45.
31. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity 2008; 29:848-62.
32. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308.
33. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 2010; 16:6019-28.
34. Nomi T, Sho M, Akahori T etal. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13:2151-7.
35. Hodi FS, O'Day SJ, McDermott DF etal. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23.